Close Menu

NEW YORK – GenapSys said today that is has raised $90 million in a Series C funding round.

The round was led by Foresite Capital and brings the total funding raised by the firm to date to $166 million.

The Redwood, California-based company plans to use the new funds to drive the commercial launch of its first sequencing instrument, the GenapSys Sequencer, which is now available for order in the US at a list price of $9,995, with a global launched planned for early 2020.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.